Eisai To Launch Digestive Drug In Thailand, Add Staff
This article was originally published in PharmAsia News
Executive Summary
Eisai plans to increase its sales staff in Thailand as it steps up marketing of its Gasmotin (mosapride) digestive-track drug in Southeast Asia where it has marketing rights. Eisai currently has 10 sales people stationed in Thailand, but expects to begin expanding the staff to 80 to sell the drug expected to be launched by the end of the year. Eisai markets the drug for Dainippon Sumitomo Pharma, its developer. Eisai has applied for approval in Indonesia, Malaysia and The Philippines, and is set to apply in Cambodia, Laos, Myanmar, Singapore, Sri Lanka and Vietnam.(Click here for more - a subscription may be required